|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290.39 USD | -1.39% |
|
+1.06% | -17.70% |
| 06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
| 06-30 | UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORPORATION | Other Pharmaceuticals | -1.39% | +1.06% | -17.70% | -7.68% | +144.85% | 13.1B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- UTHR Stock
- Charts United Therapeutics Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition